Answers are grounded in this paper and cite their sources.
Background Spinocerebellar ataxia type 36 (SCA36) is a late-onset neurodegenerative disorder caused by a GGCCTG hexanucleotide expansion in the first intron of NOP56 . This mutation produces five dipeptide repeat proteins (DPRs) via repeat-associated non-ATG (RAN) translation, including poly-glycine-proline (poly-GP) which is the most abundant DPR in SCA36. However, the specific contribution of the poly-GP to SCA36 pathogenesis and the influence of NOP56 levels on poly-GP toxicity remains poorly understood. Methods We generated zebrafish models expressing poly-GP from an alternative codon sequence lacking the GGCCTG repeat, alone or in combination with partial nop56 downregulation. Disease-associated phenotypes were evaluated by locomotor assays, immunostaining, apoptosis analysis and imaging of neuronal, muscular, and mitochondrial alterations. Proteomic and metabolomic profiling were performed to identify affected molecular pathways, followed by pathway enrichment analyses. Mitochondrial respiration was assessed using Seahorse analysis. Results Poly-GP expression alone induced locomotor impairment associated with p62 aggregation and increased TUNEL-positive cells. These phenotypes were exacerbated by partial nop56 loss-of-function, which enhanced poly-GP accumulation and promoted cerebellar malformation, motor neuron defects, and myosin-associated muscle fiber dysfunction. Proteomic profiling identified convergent alterations in ribosomal function, protein homeostasis, and cytoskeletal organization in both models. Metabolomic analysis revealed extensive metabolic remodelling in the combined model, accompanied by increased mitochondrial respiratory activity. Notably, several of these molecular alterations overlap with pathways implicated in ALS and related neurodegenerative disorders, suggesting convergent pathogenic mechanisms. Conclusions Our findings demonstrate that partial nop56 loss of function exacerbates poly-GP associated toxicity in the absence of repeat-derived RNA, supporting the hypothesis that alterations in NOP56 expression influence the molecular response to DPR accumulation in SCA36. These results provide new insights into SCA36 pathogenesis and identify molecular and metabolic pathways that may inform future biomarker and therapeutic studies.
No takes yet. Share an insight, caveat, or question.
Quelle‐Regaldie et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: